These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 34681945)

  • 21. Interferon-directed therapies for the treatment of systemic lupus erythematosus: a critical update.
    Chaichian Y; Strand V
    Clin Rheumatol; 2021 Aug; 40(8):3027-3037. PubMed ID: 33411137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Type I Interferons in Autoimmunity: Implications in Clinical Phenotypes and Treatment Response.
    Londe AC; Fernandez-Ruiz R; Julio PR; Appenzeller S; Niewold TB
    J Rheumatol; 2023 Sep; 50(9):1103-1113. PubMed ID: 37399470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic Lupus Erythematosus--A Disease with A Dysregulated Type I Interferon System.
    Hagberg N; Rönnblom L
    Scand J Immunol; 2015 Sep; 82(3):199-207. PubMed ID: 26099519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioinformatics identification of key candidate genes and pathways associated with systemic lupus erythematosus.
    Yang F; Zhai Z; Luo X; Luo G; Zhuang L; Zhang Y; Li Y; Sun E; He Y
    Clin Rheumatol; 2020 Feb; 39(2):425-434. PubMed ID: 31673979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Type I interferon antagonists in clinical development for lupus.
    Paredes JL; Niewold TB
    Expert Opin Investig Drugs; 2020 Sep; 29(9):1025-1041. PubMed ID: 32700979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunopathogenesis of systemic lupus erythematosus: An update.
    Arnaud L; Chasset F; Martin T
    Autoimmun Rev; 2024 Oct; 23(10):103648. PubMed ID: 39343084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Type I interferon in systemic lupus erythematosus.
    Crow MK
    Curr Top Microbiol Immunol; 2007; 316():359-86. PubMed ID: 17969456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anifrolumab in systemic lupus erythematosus: current knowledge and future considerations.
    Anderson E; Furie R
    Immunotherapy; 2020 Apr; 12(5):275-286. PubMed ID: 32237942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic lupus erythematosus: immunopathogenesis and novel therapeutic targets.
    Beccastrini E; D'Elios MM; Emmi G; Silvestri E; Squatrito D; Prisco D; Emmi L
    Int J Immunopathol Pharmacol; 2013; 26(3):585-96. PubMed ID: 24067455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in understanding the role of type I interferons in systemic lupus erythematosus.
    Crow MK
    Curr Opin Rheumatol; 2014 Sep; 26(5):467-74. PubMed ID: 25010440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus.
    Gensous N; Lazaro E; Blanco P; Richez C
    Expert Rev Clin Immunol; 2024; 20(1):21-30. PubMed ID: 37800604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus.
    Yao Y; Higgs BW; Richman L; White B; Jallal B
    Arthritis Res Ther; 2010; 12 Suppl 1(Suppl 1):S6. PubMed ID: 20392292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of Cardiometabolic Disease Markers by Type I Interferon Inhibition in Systemic Lupus Erythematosus.
    Casey KA; Smith MA; Sinibaldi D; Seto NL; Playford MP; Wang X; Carlucci PM; Wang L; Illei G; Yu B; Wang S; Remaley AT; Mehta NN; Kaplan MJ; White WI
    Arthritis Rheumatol; 2021 Mar; 73(3):459-471. PubMed ID: 32909675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned.
    Jones SA; Morand EF
    Drugs; 2024 Jun; 84(6):625-635. PubMed ID: 38807010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Type I Interferons in the Pathogenesis and Treatment of Autoimmune Diseases.
    Jiang J; Zhao M; Chang C; Wu H; Lu Q
    Clin Rev Allergy Immunol; 2020 Oct; 59(2):248-272. PubMed ID: 32557263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting of type I interferon in systemic autoimmune diseases.
    Crow MK; Olferiev M; Kirou KA
    Transl Res; 2015 Feb; 165(2):296-305. PubMed ID: 25468480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Type I Interferons in Systemic Lupus Erythematosus: A Journey from Bench to Bedside.
    Sim TM; Ong SJ; Mak A; Tay SH
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies.
    Lu R; Munroe ME; Guthridge JM; Bean KM; Fife DA; Chen H; Slight-Webb SR; Keith MP; Harley JB; James JA
    J Autoimmun; 2016 Nov; 74():182-193. PubMed ID: 27338520
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Abnormalities of the type I interferon signaling pathway in lupus autoimmunity.
    Gallucci S; Meka S; Gamero AM
    Cytokine; 2021 Oct; 146():155633. PubMed ID: 34340046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date.
    Felten R; Scher F; Sagez F; Chasset F; Arnaud L
    Drug Des Devel Ther; 2019; 13():1535-1543. PubMed ID: 31190735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.